| General Information | |
|---|---|
| ZINC ID | ZINC000040392423 |
| Molecular Weight (Da) | 414 |
| SMILES | C[C@H](CO)NC(=O)CCC/C=CC/C=CC/C=CC/C=CCCCCc1ccoc1 |
| Molecular Formula | C26N1O3 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 128.122 |
| HBA | 3 |
| HBD | 2 |
| Rotatable Bonds | 17 |
| Heavy Atoms | 30 |
| LogP | 5.627 |
| Activity (Ki) in nM | 1023.293 |
| Polar Surface Area (PSA) | 62.47 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | - |
| Androgen receptor binding | - |
| Plasma protein binding | 0.704 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 5 |
| Fraction csp3 | 0.5 |
| Ilogp | 4.05 |
| Xlogp3 | 7.32 |
| Wlogp | 6.05 |
| Mlogp | 5.93 |
| Silicos-it log p | 7.39 |
| Consensus log p | 6.39 |
| Esol log s | -7.22 |
| Esol solubility (mg/ml) | 0.0000289 |
| Esol solubility (mol/l) | 6.09E-08 |
| Esol class | Poorly sol |
| Ali log s | -7.95 |
| Ali solubility (mg/ml) | 0.0000053 |
| Ali solubility (mol/l) | 1.12E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -10.24 |
| Silicos-it solubility (mg/ml) | 0.00000002 |
| Silicos-it solubility (mol/l) | 5.69E-11 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -4 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.72 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -2.883 |
| Logd | 2.629 |
| Logp | 1.826 |
| F (20%) | 1 |
| F (30%) | 1 |
| Mdck | 9.11E-05 |
| Ppb | 0.999 |
| Vdss | 3.171 |
| Fu | 0.0088 |
| Cyp1a2-inh | 0.274 |
| Cyp1a2-sub | 0.742 |
| Cyp2c19-inh | 0.558 |
| Cyp2c19-sub | 0.064 |
| Cl | 4.061 |
| T12 | 0.949 |
| H-ht | 0.384 |
| Dili | 0.026 |
| Roa | 0.008 |
| Fdamdd | 0.549 |
| Skinsen | 0.923 |
| Ec | 0.003 |
| Ei | 0.011 |
| Respiratory | 0.933 |
| Bcf | 1.294 |
| Igc50 | 4.744 |
| Lc50 | 3.073 |
| Lc50dm | 3.912 |
| Nr-ar | 0.089 |
| Nr-ar-lbd | 0.003 |
| Nr-ahr | 0.003 |
| Nr-aromatase | 0.084 |
| Nr-er | 0.135 |
| Nr-er-lbd | 0.004 |
| Nr-ppar-gamma | 0.894 |
| Sr-are | 0.722 |
| Sr-atad5 | 0.005 |
| Sr-hse | 0.888 |
| Sr-mmp | 0.464 |
| Sr-p53 | 0.053 |
| Vol | 468.608 |
| Dense | 0.882 |
| Flex | 1.8 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 1 |
| Qed | 0.241 |
| Synth | 3.508 |
| Fsp3 | 0.5 |
| Mce-18 | 12 |
| Natural product-likeness | 0.772 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Rejected |
| Goldentriangle | Accepted |